Akcea Therapeutics (NASDAQ:AKCA) was upgraded by equities research analysts at ValuEngine from a “hold” rating to a “buy” rating in a report issued on Tuesday.
Separately, Zacks Investment Research lowered Akcea Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, February 8th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the stock. Akcea Therapeutics currently has an average rating of “Hold” and an average price target of $38.20.
Shares of Akcea Therapeutics stock traded down $1.68 during trading on Tuesday, reaching $26.01. The stock had a trading volume of 423,172 shares, compared to its average volume of 171,357. The firm has a market cap of $2.47 billion, a price-to-earnings ratio of -11.61 and a beta of 1.58. Akcea Therapeutics has a 52 week low of $15.73 and a 52 week high of $40.75.
Akcea Therapeutics Company Profile
Akcea Therapeutics, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with cardiometabolic diseases caused by lipid disorders in the United States and internationally. It develops Volanesorsen, which has completed Phase 3 clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase 3 clinical study for the treatment of familial partial lipodystrophy.
Read More: What are economic reports?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Akcea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.